How I helped Pfizer think through the ethics of Viagra

AdobeTwenty-fiveyearsago,75-year-oldBobDole—formerRepublicanpresidentialcandidateandU.S.senatorfromK WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.




fashion

author：leisure time    Page View：221
The logo of Neurocrine Biosciences on a phone screen with stocks chart in the background — coverage from STAT
Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

advertisement

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： FDA advisers back CAR
Next article： The high cost of giving birth even with insurance